Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial

Publication date

2025-10-07

Authors

van der Wel, Anne W.T.
Frank, Chryselle M.C.
Bout-Rebel, Rebekka
Duijnhoven, Ruben G.
van Bree, Bo E.
Valkenburg, Olivier
Al-Nasiry, Salwan
van Oppenraaij, Robbert H.F.
Vogelvang, Tatjana E.
Westerhuis, Michelle E.M.H.

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

taverne

Abstract

Importance: Pregnant individuals with polycystic ovary syndrome (PCOS) present with a higher risk of pregnancy complications, including gestational diabetes, preeclampsia, and preterm birth. Myo-inositol supplementation may reduce these risks. Objective: To determine whether daily supplementation with myo-inositol during pregnancy among individuals with PCOS reduces the risk of a composite outcome of gestational diabetes, preeclampsia, and preterm birth. Design, Setting, and Participants: This double-blind, placebo-controlled, randomized trial was conducted at 13 hospitals in the Netherlands. Pregnant individuals with PCOS who were between 8 and 16 weeks' gestation were enrolled between June 2019 and March 2023. Final follow-up was complete on December 27, 2023. Analyses were conducted July 2024. Interventions: Participants were randomized on a 1:1 basis to receive sachets with either myo-inositol, 2 g, with 0.2 mg of folic acid twice daily (n = 230) or matching placebo with 0.2 mg of folic acid only (n = 234) until delivery. Main Outcomes and Measures: The primary outcome was a composite of gestational diabetes, preeclampsia, or preterm birth (before 37 weeks' gestation). Results: Among 464 participants, the mean (SD) age was 31.5 (3.8) years; 18 participants (3.9%) reported Asian race and 395 (86.1%) reported White race. The prevalence of biochemical hyperandrogenism was higher at baseline in the myo-inositol group than the placebo group (29.0% [53 of 180] vs 18.5% [37 of 193]). A primary outcome event occurred in 25.0% (n = 56) of participants in the myo-inositol group and 26.8% (n = 61) in the placebo group (relative risk, 0.93 [95% CI, 0.68-1.28]; P = .67). Conclusions and Relevance: Myo-inositol supplementation during pregnancy did not reduce the incidence of a composite of gestational diabetes, preeclampsia, or preterm birth in patients with PCOS. Trial Registration: onderzoekmetmensen.nl Identifier: NL67329.078.18.

Keywords

Taverne, General Medicine

Citation

van der Wel, A W T, Frank, C M C, Bout-Rebel, R, Duijnhoven, R G, van Bree, B E, Valkenburg, O, Al-Nasiry, S, van Oppenraaij, R H F, Vogelvang, T E, Westerhuis, M E M H, van de Nieuwenhof, H P, Gielen, S C J P, Bandell, M L, Bekker, M N, Wouters, M G A J, Mijatovic, V, Franx, A, Lambalk, C B, Broekmans, F J M, de Weerd, S, Gerards, J M H, Baalman, J H, van Disseldorp, J, Langenveld, J, Gunning, M N, Frederix, G W J, Painter, R C, Fauser, B C J M, Laven, J S E & van Rijn, B B 2025, 'Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome : A Randomized Clinical Trial', JAMA, vol. 334, no. 13, pp. 1151-1159. https://doi.org/10.1001/jama.2025.13668